Kane Biotech Inc., a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops pet oral care products under the StrixNB and bluestem brands; animal and human wound care solutions under the DispersinB name; shampoos for dogs, cats, and horses under the Alosera name; and medical device coatings under the Aledex name. It also offers scalp care products under the DermaKB brand name, wound care products under the Coactiv+ brand name, as well as other products under the goldstem, silkstem, and DermaKB Biofilm brand names. Kane Biotech Inc. was incorporated in 2001 and is based in Winnipeg, Canada.
Show more...
CEO
Dr. Robert B. Huizinga CNeph(C), M.Sc., MSc(Epi), Ph.D., R.N., RN NNC
The current price of KNBIF is $0.02 USD — it has increased by +0% in the past 24 hours. Watch Kane Biotech stock price performance more closely on the chart.
What is Kane Biotech stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Kane Biotech stocks are traded under the ticker KNBIF.
Is Kane Biotech stock price growing?▼
KNBIF stock has risen by +0.46% compared to the previous week, the month change is a +4.76% rise, over the last year Kane Biotech has showed a -68.66% decrease.
What is Kane Biotech market cap?▼
Today Kane Biotech has the market capitalization of 3.68M
What were Kane Biotech earnings last quarter?▼
KNBIF earnings for the last quarter are -0.01 USD per share, whereas the estimation was N/A USD resulting in a N/A surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Kane Biotech revenue for the last year?▼
Kane Biotech revenue for the last year amounts to 312,881.45 USD.
What is Kane Biotech net income for the last year?▼
KNBIF net income for the last year is -1.53M USD.
In which sector is Kane Biotech located?▼
Kane Biotech operates in the Health Care sector.
When did Kane Biotech complete a stock split?▼
The last stock split for Kane Biotech was on March 13, 2017 with a ratio of 1:5.